Evidence map›Paper›PMID 25361584›Full record

ArticleInternational journal of epidemiology2015

Subgroups at high risk for ischaemic heart disease:identification and validation in 67 000 individuals from the general population.

Ruth Frikke-Schmidt, Anne Tybjærg-Hansen, Greg Dyson, Christiane L Haase, Marianne Benn, Børge G Nordestgaard, Charles F Sing

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of epidemiology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Ruth Frikke-SchmidtDepartment of Clinical Biochemistry, Rigshospitalet, The Copenhagen General Population Study, Herlev Hospital, The Copenhagen City Heart Study, Frederiksberg Hospital, Copenhagen, Denmark, Department of Oncology, Wayne State University, Detroit, USA, Department of Clinical Biochemistry, Gentofte Hospital, Department of Clinical Biochemistry, Herlev Hospital, Copenhagen, Denmark, Department of Human Genetics, University of Michigan, Ann Arbor, USA and Copenhagen University Hospital and Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark. Department of Clinical Biochemistry, Rigshospitalet, The Copenhagen General Population Study, Herlev Hospital, The Copenhagen City Heart Study, Frederiksberg Hospital, Copenhagen, Denmark, Department of Oncology, Wayne State University, Detroit, USA, Department of Clinical Biochemistry, Gentofte Hospital, Department of Clinical Biochemistry, Herlev Hospital, Copenhagen, Denmark, Department of Human Genetics, University of Michigan, Ann Arbor, USA and Copenhagen University Hospital and Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark. ruth.frikke-schmidt@regionh.dk.
Anne Tybjærg-HansenDepartment of Clinical Biochemistry, Rigshospitalet, The Copenhagen General Population Study, Herlev Hospital, The Copenhagen City Heart Study, Frederiksberg Hospital, Copenhagen, Denmark, Department of Oncology, Wayne State University, Detroit, USA, Department of Clinical Biochemistry, Gentofte Hospital, Department of Clinical Biochemistry, Herlev Hospital, Copenhagen, Denmark, Department of Human Genetics, University of Michigan, Ann Arbor, USA and Copenhagen University Hospital and Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark. Department of Clinical Biochemistry, Rigshospitalet, The Copenhagen General Population Study, Herlev Hospital, The Copenhagen City Heart Study, Frederiksberg Hospital, Copenhagen, Denmark, Department of Oncology, Wayne State University, Detroit, USA, Department of Clinical Biochemistry, Gentofte Hospital, Department of Clinical Biochemistry, Herlev Hospital, Copenhagen, Denmark, Department of Human Genetics, University of Michigan, Ann Arbor, USA and Copenhagen University Hospital and Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark. Department of Clinical Biochemistry, Rigshospitalet, The Copenhagen General Population Study, Herlev Hospital, The Copenhagen City Heart Study, Frederiksberg Hospital, Copenhagen, Denmark, Department of Oncology, Wayne State University, Detroit, USA, Department of Clinical Biochemistry, Gentofte Hospital, Department of Clinical Biochemistry, Herlev Hospital, Copenhagen, Denmark, Department of Human Genetics, University of Michigan, Ann Arbor, USA and Copenhagen University Hospital and Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
Greg DysonDepartment of Clinical Biochemistry, Rigshospitalet, The Copenhagen General Population Study, Herlev Hospital, The Copenhagen City Heart Study, Frederiksberg Hospital, Copenhagen, Denmark, Department of Oncology, Wayne State University, Detroit, USA, Department of Clinical Biochemistry, Gentofte Hospital, Department of Clinical Biochemistry, Herlev Hospital, Copenhagen, Denmark, Department of Human Genetics, University of Michigan, Ann Arbor, USA and Copenhagen University Hospital and Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
Christiane L HaaseDepartment of Clinical Biochemistry, Rigshospitalet, The Copenhagen General Population Study, Herlev Hospital, The Copenhagen City Heart Study, Frederiksberg Hospital, Copenhagen, Denmark, Department of Oncology, Wayne State University, Detroit, USA, Department of Clinical Biochemistry, Gentofte Hospital, Department of Clinical Biochemistry, Herlev Hospital, Copenhagen, Denmark, Department of Human Genetics, University of Michigan, Ann Arbor, USA and Copenhagen University Hospital and Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
Marianne BennDepartment of Clinical Biochemistry, Rigshospitalet, The Copenhagen General Population Study, Herlev Hospital, The Copenhagen City Heart Study, Frederiksberg Hospital, Copenhagen, Denmark, Department of Oncology, Wayne State University, Detroit, USA, Department of Clinical Biochemistry, Gentofte Hospital, Department of Clinical Biochemistry, Herlev Hospital, Copenhagen, Denmark, Department of Human Genetics, University of Michigan, Ann Arbor, USA and Copenhagen University Hospital and Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
Børge G NordestgaardDepartment of Clinical Biochemistry, Rigshospitalet, The Copenhagen General Population Study, Herlev Hospital, The Copenhagen City Heart Study, Frederiksberg Hospital, Copenhagen, Denmark, Department of Oncology, Wayne State University, Detroit, USA, Department of Clinical Biochemistry, Gentofte Hospital, Department of Clinical Biochemistry, Herlev Hospital, Copenhagen, Denmark, Department of Human Genetics, University of Michigan, Ann Arbor, USA and Copenhagen University Hospital and Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark. Department of Clinical Biochemistry, Rigshospitalet, The Copenhagen General Population Study, Herlev Hospital, The Copenhagen City Heart Study, Frederiksberg Hospital, Copenhagen, Denmark, Department of Oncology, Wayne State University, Detroit, USA, Department of Clinical Biochemistry, Gentofte Hospital, Department of Clinical Biochemistry, Herlev Hospital, Copenhagen, Denmark, Department of Human Genetics, University of Michigan, Ann Arbor, USA and Copenhagen University Hospital and Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark. Department of Clinical Biochemistry, Rigshospitalet, The Copenhagen General Population Study, Herlev Hospital, The Copenhagen City Heart Study, Frederiksberg Hospital, Copenhagen, Denmark, Department of Oncology, Wayne State University, Detroit, USA, Department of Clinical Biochemistry, Gentofte Hospital, Department of Clinical Biochemistry, Herlev Hospital, Copenhagen, Denmark, Department of Human Genetics, University of Michigan, Ann Arbor, USA and Copenhagen University Hospital and Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
Charles F SingDepartment of Clinical Biochemistry, Rigshospitalet, The Copenhagen General Population Study, Herlev Hospital, The Copenhagen City Heart Study, Frederiksberg Hospital, Copenhagen, Denmark, Department of Oncology, Wayne State University, Detroit, USA, Department of Clinical Biochemistry, Gentofte Hospital, Department of Clinical Biochemistry, Herlev Hospital, Copenhagen, Denmark, Department of Human Genetics, University of Michigan, Ann Arbor, USA and Copenhagen University Hospital and Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.

Funding

Variable DNA sites predicting interindividual variation in health measuresP50GM065509 · NIGMS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI SING, CHARLES · 2001 to 2011
$27.5M
Modeling DNA Diversity in Reverse Cholesterol TransportR01HL072905 · NHLBI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI SING, CHARLES · 2003 to 2012
$5.3M
NHLBI NIH HHS HL072905NHLBI NIH HHS R01 HL072905NIGMS NIH HHS GM065509NIGMS NIH HHS P50 GM065509
6 · The paper itself

Abstract

backgroundThe aetiology of ischaemic heart disease (IHD) is complex and is influenced by a spectrum of environmental factors and susceptibility genes. Traditional statistical modelling considers such factors to act independently in an additive manner. The Patient Rule-Induction Method (PRIM) is a multi-model building strategy for evaluating risk attributable to context-dependent gene and environmental effects.

methodsPRIM was applied to 9073 participants from the prospective Copenhagen City Heart Study (CCHS). Gender-specific cumulative incidences were estimated for subgroups defined by categories of age, smoking, hypertension, diabetes, body mass index, total cholesterol, high-density lipoprotein cholesterol and triglycerides and by 94 single nucleotide variants (SNVs).Cumulative incidences for subgroups were validated using an independently ascertained sample of 58 240 participants from the Copenhagen General Population Study (CGPS).

resultsIn the CCHS the overall cumulative incidences were 0.17 in women and 0.21 in men. PRIM identified six and four mutually exclusive subgroups in women and men, respectively, with cumulative incidences of IHD ranging from 0.02 to 0.34. Cumulative incidences of IHD generated by PRIM in the CCHS were validated in four of the six subgroups of women and two of the four subgroups of men in the CGPS.

conclusionsPRIM identified high-risk subgroups characterized by specific contexts of selected values of traditional risk factors and genetic variants. These subgroups were validated in an independently ascertained cohort study. Thus, a multi-model strategy may identify groups of individuals with substantially higher risk of IHD than the overall risk for the general population.

Indexed as

EnvironmentGenetic Predisposition to DiseaseAdultAgedAged, 80 and overAge FactorsBody Mass IndexCoronary Artery DiseaseDenmarkDiabetes MellitusFemaleHumansHypertensionLipidsMaleMiddle AgedLipidsCardiovascular diseasegenetic epidemiologyrisk factor

Identifiers

PMID25361584
PMCPMC4339759

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.